Sign up
Pharma Capital

'We've had a very good year' - Abzena plc Chief John Burt

John Burt, chief executive of Abzena plc (LON:ABZA) tells Proactive full-year revenue for the 12 months to the end of March 2017 jumped by almost 90%, with underlying losses reduced as they prepare for “significant growth”.

 

View full ABZA profile

Abzena plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.